Cytokine profile: recent advances in pathogenesis of inflammatory bowel diseases

Особенности цитокинового профиля: последние достижения в изучении патогенеза ВЗК
Ainur Doszhan 1, Rosa Bektayeva 1, Aiman Galiyeva 1, Aliya Kurmankina 2, Kapura Adrissova 1, Kazbek Agibayev 3, Maiya Zhumabayeva 4
More Detail
1 Department of Gastroenterology and Infectious Diseases, Astana Medical University, Astana, Republic of Kazakhstan
2 Clinical diagnostic laboratory, Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan, Astana, Republic of Kazakhstan
3 Center for Coloproctology and Surgical Infections, Municipal Hospital No1, Astana, Republic of Kazakhstan
4 Department of Scientific Research Management, National Scientific Medical Center, Astana, Republic of Kazakhstan
J CLIN MED KAZ, Volume 1, Issue 47, pp. 14-17. https://doi.org/10.23950/1812-2892-JCMK-00544
OPEN ACCESS 3229 Views 2257 Downloads
Download Full Text (PDF)

ABSTRACT

Inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, remain an urgent problem of clinical gastroenterology. Although the etiology of both diseases is still unknown, in recent years progress has been made in studying of pathogenesis of inflammatory processes in patients with inflammatory bowel diseases. In particular, recent data from the foreign literature on the immune dysregulation demonstrate the important roles of novel IL-1 family and the IL-6 family in the inflammatory bowel diseases development, which can determine their diagnostic value and the personalized therapeutic strategy in such patients in the future.
Keywords: ulcerative colitis, Crohn’s disease, cytokine profile, tumor necrosis factor, interleukins

CITATION

Doszhan A, Bektayeva R, Galiyeva A, Kurmankina A, Adrissova K, Agibayev K, et al. Cytokine profile: recent advances in pathogenesis of inflammatory bowel diseases. Journal of Clinical Medicine of Kazakhstan. 2018;1(47):14-7. https://doi.org/10.23950/1812-2892-JCMK-00544

REFERENCES

  • Guan Q, Zhang J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediators of Inflammation. 2017; 2017:4810258.
  • Gastroenterologiya. Natsional’noe rukovodstvo: kratkoe izdanie (National guideline: short edition) [in Russian]. Moscow: GEOTAR-Media; 2015. p. 480.
  • Szigethy EV, McLafferty LA, Goyal AF. Inflammatory bowel disease. Child and Adolescent Psychiatric Clinics of North America. 2010; 19(2):301–318.
  • Ivashkin VT, Shelygin YA, Abdulganieva D I, Abdulkhakov RA, Alekseeva O P, Achkasov SI et al. Rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu vzroslykh bol’nykh yazvennym kolitom (Guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists for diagnosis and treatment of adults with ulcerative colitis) [in Russian]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2015; 1:48-65.
  • Loddo IN, Romano CC. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Frontiers in Immunology. 2015; 6:551.
  • Neurath MF. Cytokines in inflammatory bowel disease. Nature Reviews Immunology. 2014; 14(5):329–342.
  • Souza HS, Fiocchi CV. Immunopathogenesis of IBD: current state of the art. Nature Reviews Gastroenterology & Hepatology. 2016; 13(1):13–27.
  • Ince MN, Elliott DE. Immunologic and molecular mechanisms in inflammatory bowel disease. The Surgical Clinics of North America. 2007; 87(3):681–696.
  • Chen ML., Sundrud MS. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflammatory Bowel Diseases. 2016; 22(5):1157–1167.
  • Sagynbaeva VE, Lazebnik LB, Knyazev OV, Efremov LI. Dinamika provospalitel’nykh tsitokinov na fone biologicheskoi terapii vospalitel’nykh zabolevanii kishechnika (Dynamics of proinflammatory cytokines after the biological therapy of inflammatory bowel diseases) [in Russian]. Eksperimental’naya i klinicheskaya gastroenterologiya. 2012; 3:47 – 58.
  • Locksley RM, Killeen NN, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001; 104:487-501.
  • Műzes GM, Molnár BN, Tulassay ZF. Changes of the cytokine profile in inflammatory bowel diseases. World Journal of Gastroenteroly. 2012; 18(41):5848-5861.
  • Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc ResTech. 2000; 50:184-195.
  • Smith CA, Farrah TM, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994; 76:959-962.
  • Murch SR, Braegger CD, Walker-Smith JA, MacDonald T. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993; 34:1705-1709.
  • Pastorelli LW, Garg RR, Hoang S, Spina LN, Mattioli B, Scarpa M et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA. 2010; 107:8017-8022.
  • Begue BN, Wajant HN, Bambou JC, Dubuquoy LN, Siegmund DH, Beaulieu JF et al. Implication of TNF-related apoptosisinducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology. 2006; 130:1962-1974.
  • Bamias GB, Martin CC, Marini M, Hoang S, Mishina MN, Ross W et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003; 171:4868-4874. 
  • Matveeva LV, Mosina LM. Rol’ tsitokinov semeistva interleikina-1 v zheludochnom kantserogeneze (The role of cytokines of the interleukin-1 family in gastric carcinogenesis) [in Russian]. Vestnik RAMN.2012; 11.
  • Sims JE, Nicklin MJ, Bazan JF, Barton JL, Busfield SJ, Ford JE et al. A new nomenclature for IL-1-family genes. Trends Immunol. 2001; 22:536–537.
  • Garlanda CB, Dinarello CA, Mantovani AA. The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003–1018.
  • Palomo JN, Dietrich DG, Martin P, Palmer GB, Gabay C. The interleukin (IL)-1 cytokine family–balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015; 76(1):25–37.
  • Boulanger MJ, Bankovich AJ, Kortemme T, Baker D, Garcia KC. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell. 2003; 12:577-589.
  • Nasonov EL, Mazurov V I, Usacheva YV. Razrabotki otechestvennykh original’nykh genno-inzhenernykh biologicheskikh preparatov dlya lecheniya immunovospalitel’nykh revmaticheskikh zabolevanii (Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases) [in Russian]. Rheumatology Science and Practice. 2017;55(2):201-210.
  • Hoene MB, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obesity reviews. 2008; 9:20–29.
  • Li Y, Haar CD, Chen M, Deuring J, Gerrits MM, Smits RB, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010; 59:227-235.
  • Mudter J, Neurath MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis. 2007; 13:1016-1023.